Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Spins Off From BioTime

NEW YORK (GenomeWeb) – OncoCyte said today that it has spun off as a publicly traded company from BioTime and has begun trading on the NYSE MKT under the symbol OCX.

On Dec. 31, BioTime distributed approximately 4.75 million shares of OncoCyte common stock to its shareholders in the ratio of one share of OncoCyte stock for every 20 BioTime common shares owned. There are now 25.4 million shares outstanding of OncoCyte, of which BioTime owns 58.55 percent.

Based in Alameda, California, OncoCyte focuses primarily on developing non-invasive blood- and urine-based diagnostic tests for the early detection of cancer. The company is developing tests for confirmatory diagnosis of lung, bladder, and breast cancer using proprietary sets of gene and protein markers.

In August, OncoCyte said that it had expanded an agreement with the Wistar Institute to develop a diagnostic test for the early detection of lung cancer using gene expression biomarkers discovered at Wistar.

"Becoming a publicly traded company is a key milestone in our development," OncoCyte CEO William Annett said in a statement. "We will continue to leverage the team's diagnostics, commercial, and public company expertise to achieve significant milestones in 2016 with the goal of maximizing shareholder value. These milestones will include preparation for the commercial launch of our first product, which, subject to the successful completion of our R&D program, will be a confirmatory diagnostic test for lung cancer."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.